Minerva Neurosciences Inc (NERV)

Over the past six months, Minerva Neurosciences' stock price has been impacted by several key events. In October 2025, the company secured up to $200 million in financing, leading to a significant surge in the stock price. In November 2025, Dr. Inderjit Kaul was appointed to the board of directors. In December 2025, Jefferies initiated coverage of NERV with a Hold rating, and the company's price target was increased. Minerva Neurosciences filed for an offering of shares by selling stockholders in December 2025. In January and February 2026, the company announced it would host a virtual KOL event to discuss roluperidone and discussed roluperidone as a potential first treatment for negative symptoms of schizophrenia. As of February 7, 2026, the stock had experienced a significant increase over the past six months.

As a clinical-stage biopharmaceutical company, Minerva Neurosciences, Inc. is primarily focused on research and development, so there is no readily available information or indication of demand seasonality for its products and services at this stage.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases, operating in the Health Technology sector, specifically the Pharmaceuticals: Major industry. Their lead product candidate, roluperidone, is being investigated for negative symptoms in schizophrenia and is designed to modulate sigma and adrenergic receptors without dopaminergic activity. MIN-301 is in development for Parkinson's disease, and MIN-117 is being evaluated for major depressive disorder.

Minerva Neurosciences, Inc. is headquartered in Burlington, Massachusetts, USA. They have an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation for roluperidone, allowing for global research, marketing, and import beyond Asia.

Minerva Neurosciences' brand reputation has been largely influenced by developments surrounding roluperidone. The announcement of financing in October 2025 generated optimism on social media, driven by the potential for a breakthrough in CNS therapies. Discussions also included warnings about potential risks, indicating a mixed conversation around the company's prospects. The company also reported a profitable 2024, despite ongoing challenges with the FDA regarding roluperidone's New Drug Application.

Minerva Neurosciences, Inc. has institutional owners and shareholders, holding a total of shares. Major institutional owners include Federated Hermes, Inc., Vanguard Group Inc, Renaissance Technologies Llc, Geode Capital Management, Llc, BlackRock, Inc., Apella Capital, LLC, and Farallon Capital Management, L.L.C. Insiders hold a portion of the outstanding shares.